Influenza virus vaccine intranasal - ID Biomedical

Drug Profile

Influenza virus vaccine intranasal - ID Biomedical

Alternative Names: FluINsure; Influenza virus vaccine intranasal - Intellivax

Latest Information Update: 15 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ID Biomedical Corporation; Intellivax
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 28 Feb 2007 Discontinued - Phase-I for Influenza virus infections in USA (Intranasal)
  • 28 Feb 2007 Discontinued - Phase-II for Influenza virus infections in Canada (Intranasal)
  • 28 Feb 2007 Discontinued - Phase-II for Influenza virus infections in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top